Results of logistic regression analysis on DNA repair genotypes and selected toxicity categories
| Gene . | No. . | Patients . | Liver toxicity . | Lung toxicity . | Metabolic toxicity . | GU toxicity . | GI toxicity . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. . | % . | OR . | 95% CI . | OR . | 95% CI . | OR . | 95% CI . | OR . | 95% CI . | OR . | 95% CI . | ||
| APEX1 | 178 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| GG | 52 | 29.21 | 1 | NA | 1 | NA | 1 | NA | 1 | NA | 1 | NA | |
| GT | 73 | 41.01 | 1.5 | 0.70-3.18 | 1.48 | .69-3.19 | 1.31 | 0.51-3.37 | 1.06 | 0.41-2.74 | 0.99 | 0.52-1.90 | |
| TT | 53 | 29.78 | 1.24 | 0.56-2.75 | 1.39 | 0.61-3.24 | 0.61 | 0.24-1.52 | 0.71 | 0.27-1.84 | 0.59 | 0.29-1.20 | |
| GT or TT | 126 | 70.79 | 1.38 | 0.70-2.67 | 1.45 | 0.71-2.87 | 0.92 | 0.39-2.02 | 0.88 | 0.38-2.05 | 0.8 | 0.44-1.46 | |
| XRCC1 | 194 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| GG | 91 | 46.91 | 1 | NA | 1 | NA | 1 | NA | 1 | NA | 1 | NA | |
| GA | 87 | 44.85 | 0.7 | 0.37-1.31 | 1 | 0.53-1.91 | 1.24 | 0.59-2.66 | 0.8 | 0.35-1.80 | 0.68 | 0.39-1.17 | |
| AA | 16 | 8.25 | 1.2 | 0.39-4.56 | 0.96 | 0.33-3.21 | 1.94 | 0.49-12.98 | 0.78 | 0.22-3.70 | 1.27 | 0.46-3.50 | |
| GA or AA | 103 | 53.09 | 0.76 | 0.41-1.39 | 0.99 | 0.54-1.83 | 1.32 | 0.64-2.75 | 0.8 | 0.36-1.72 | 0.74 | 0.44-1.25 | |
| XRCC3 | 185 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| CC | 94 | 50.81 | 1 | NA | 1 | NA | 1 | NA | 1 | NA | 1 | NA | |
| CT | 75 | 40.54 | 0.95 | 0.50-1.83 | 1.65 | 0.86-3.24 | 1.18 | 0.56-2.57 | 0.97 | 0.44-2.19 | 0.98 | 0.56-1.71 | |
| TT | 16 | 8.65 | 0.32 | 0.11-0.95 | 2.53 | 0.76-11.51 | 1.84 | 0.46-12.30 | 0.79 | 0.22-3.74 | 0.53 | 0.21-1.33 | |
| CT or TT | 91 | 49.19 | 0.79 | 0.43-1.45 | 1.77 | 0.95-3.36 | 1.27 | 0.61-2.65 | 0.93 | 0.44-2.01 | 0.87 | 0.51-147 | |
| ERCC1 | 199 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| CC | 149 | 74.87 | 1 | NA | 1 | NA | 1 | NA | 1 | NA | 1 | NA | |
| CA | 46 | 23.12 | 0.69 | 0.35-1.41 | 1.82 | 0.84-4.27 | 0.41 | 0.19-0.90 | 0.75 | 0.33-1.84 | 1.12 | 0.61-2.05 | |
| AA | 4 | 2.01 | 1.33 | 0.18-26.60 | 0.16 | 0.02-1.02 | 0.23 | 0.04-1.81 | Inf (n=4)* | 0.31−∞* | 0.58 | 0.08-4.18 | |
| CA or AA | 50 | 25.13 | 0.73 | 0.37-1.46 | 1.37 | 0.68-2.95 | 0.39 | 0.19-0.82 | 0.84 | 0.37-2.04 | 1.07 | 0.59-1.93 | |
| XPD Lys751Gln | 194 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| AA | 84 | 43.30 | 1 | NA | 1 | NA | 1 | NA | 1 | NA | 1 | NA | |
| AC | 83 | 42.78 | 1.59 | 0.83-3.11 | 0.54 | 0.28-1.02 | 1.57 | 0.73-3.48 | 0.88 | 0.37-2.06 | 0.66 | 0.38-1.16 | |
| CC | 27 | 13.92 | 1.06 | 0.44-2.68 | 1.40 | 0.50-4.54 | 0.95 | 0.37-2.68 | 0.38 | 0.14-1.09 | 1.36 | 0.62-3.01 | |
| AC or CC | 110 | 56.70 | 1.42 | 0.78-2.61 | 0.65 | 0.35-1.20 | 1.35 | 0.68-2.72 | 0.69 | 0.31-1.47 | 0.80 | 0.47-1.34 | |
| XPD Asp312Asn | 190 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| GG | 95 | 50.00 | 1 | NA | 1 | NA | 1 | NA | 1 | NA | 1 | NA | |
| GA | 76 | 40.00 | 1.25 | 0.65-2.45 | 0.76 | 0.40-1.44 | 1.28 | 0.60-2.81 | 0.79 | 0.34-1.87 | 0.54 | 0.31-0.95 | |
| AA | 19 | 10.00 | 0.44 | 0.17-1.18 | 0.78 | 0.28-2.39 | 0.79 | 0.27-2.64 | 0.27 | 0.09-0.81 | 1.07 | 0.42-2.73 | |
| GA or AA | 95 | 50.00 | 0.99 | 0.54-1.82 | 0.76 | 0.41-1.39 | 1.14 | 0.57-2.32 | 0.60 | 0.27-1.28 | 0.62 | 0.36-1.04 | |
| Gene . | No. . | Patients . | Liver toxicity . | Lung toxicity . | Metabolic toxicity . | GU toxicity . | GI toxicity . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. . | % . | OR . | 95% CI . | OR . | 95% CI . | OR . | 95% CI . | OR . | 95% CI . | OR . | 95% CI . | ||
| APEX1 | 178 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| GG | 52 | 29.21 | 1 | NA | 1 | NA | 1 | NA | 1 | NA | 1 | NA | |
| GT | 73 | 41.01 | 1.5 | 0.70-3.18 | 1.48 | .69-3.19 | 1.31 | 0.51-3.37 | 1.06 | 0.41-2.74 | 0.99 | 0.52-1.90 | |
| TT | 53 | 29.78 | 1.24 | 0.56-2.75 | 1.39 | 0.61-3.24 | 0.61 | 0.24-1.52 | 0.71 | 0.27-1.84 | 0.59 | 0.29-1.20 | |
| GT or TT | 126 | 70.79 | 1.38 | 0.70-2.67 | 1.45 | 0.71-2.87 | 0.92 | 0.39-2.02 | 0.88 | 0.38-2.05 | 0.8 | 0.44-1.46 | |
| XRCC1 | 194 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| GG | 91 | 46.91 | 1 | NA | 1 | NA | 1 | NA | 1 | NA | 1 | NA | |
| GA | 87 | 44.85 | 0.7 | 0.37-1.31 | 1 | 0.53-1.91 | 1.24 | 0.59-2.66 | 0.8 | 0.35-1.80 | 0.68 | 0.39-1.17 | |
| AA | 16 | 8.25 | 1.2 | 0.39-4.56 | 0.96 | 0.33-3.21 | 1.94 | 0.49-12.98 | 0.78 | 0.22-3.70 | 1.27 | 0.46-3.50 | |
| GA or AA | 103 | 53.09 | 0.76 | 0.41-1.39 | 0.99 | 0.54-1.83 | 1.32 | 0.64-2.75 | 0.8 | 0.36-1.72 | 0.74 | 0.44-1.25 | |
| XRCC3 | 185 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| CC | 94 | 50.81 | 1 | NA | 1 | NA | 1 | NA | 1 | NA | 1 | NA | |
| CT | 75 | 40.54 | 0.95 | 0.50-1.83 | 1.65 | 0.86-3.24 | 1.18 | 0.56-2.57 | 0.97 | 0.44-2.19 | 0.98 | 0.56-1.71 | |
| TT | 16 | 8.65 | 0.32 | 0.11-0.95 | 2.53 | 0.76-11.51 | 1.84 | 0.46-12.30 | 0.79 | 0.22-3.74 | 0.53 | 0.21-1.33 | |
| CT or TT | 91 | 49.19 | 0.79 | 0.43-1.45 | 1.77 | 0.95-3.36 | 1.27 | 0.61-2.65 | 0.93 | 0.44-2.01 | 0.87 | 0.51-147 | |
| ERCC1 | 199 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| CC | 149 | 74.87 | 1 | NA | 1 | NA | 1 | NA | 1 | NA | 1 | NA | |
| CA | 46 | 23.12 | 0.69 | 0.35-1.41 | 1.82 | 0.84-4.27 | 0.41 | 0.19-0.90 | 0.75 | 0.33-1.84 | 1.12 | 0.61-2.05 | |
| AA | 4 | 2.01 | 1.33 | 0.18-26.60 | 0.16 | 0.02-1.02 | 0.23 | 0.04-1.81 | Inf (n=4)* | 0.31−∞* | 0.58 | 0.08-4.18 | |
| CA or AA | 50 | 25.13 | 0.73 | 0.37-1.46 | 1.37 | 0.68-2.95 | 0.39 | 0.19-0.82 | 0.84 | 0.37-2.04 | 1.07 | 0.59-1.93 | |
| XPD Lys751Gln | 194 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| AA | 84 | 43.30 | 1 | NA | 1 | NA | 1 | NA | 1 | NA | 1 | NA | |
| AC | 83 | 42.78 | 1.59 | 0.83-3.11 | 0.54 | 0.28-1.02 | 1.57 | 0.73-3.48 | 0.88 | 0.37-2.06 | 0.66 | 0.38-1.16 | |
| CC | 27 | 13.92 | 1.06 | 0.44-2.68 | 1.40 | 0.50-4.54 | 0.95 | 0.37-2.68 | 0.38 | 0.14-1.09 | 1.36 | 0.62-3.01 | |
| AC or CC | 110 | 56.70 | 1.42 | 0.78-2.61 | 0.65 | 0.35-1.20 | 1.35 | 0.68-2.72 | 0.69 | 0.31-1.47 | 0.80 | 0.47-1.34 | |
| XPD Asp312Asn | 190 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| GG | 95 | 50.00 | 1 | NA | 1 | NA | 1 | NA | 1 | NA | 1 | NA | |
| GA | 76 | 40.00 | 1.25 | 0.65-2.45 | 0.76 | 0.40-1.44 | 1.28 | 0.60-2.81 | 0.79 | 0.34-1.87 | 0.54 | 0.31-0.95 | |
| AA | 19 | 10.00 | 0.44 | 0.17-1.18 | 0.78 | 0.28-2.39 | 0.79 | 0.27-2.64 | 0.27 | 0.09-0.81 | 1.07 | 0.42-2.73 | |
| GA or AA | 95 | 50.00 | 0.99 | 0.54-1.82 | 0.76 | 0.41-1.39 | 1.14 | 0.57-2.32 | 0.60 | 0.27-1.28 | 0.62 | 0.36-1.04 | |
NA indicates not applicable.
*No GU toxicities among patients with ERCC1 AA genotype resulted in infinite OR estimates.